Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday'

Galectin Therapeutics Inc. (NASDAQ:GALT) ("Galectin" or the "Company"), a clinical-s

Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into com

Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess

Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers incl

Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,

Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and c

Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosi

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) wit

Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies f

NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotec

NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which missed the

NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the lead

Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeu

NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), a clinica

LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics,

Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the an

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get

Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get

Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirr

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that i

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that i

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights li

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.

HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) wit

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the an

HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the an

https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18